» Articles » PMID: 24449092

Predicting Non-adherence in Patients with Familial Hypercholesterolemia

Overview
Specialty Pharmacology
Date 2014 Jan 23
PMID 24449092
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Familial hypercholesterolemia (FH) is an autosomal dominant disorder associated with a high risk of premature coronary heart disease (CHD). CHD prevention consists of lifestyle changes combined with lifelong statin treatment. Good adherence to statins reduces the risk of events substantially. This study was designed to identify determinants of non-adherence and to develop a model predicting non-adherence.

Methods: A single centre survey included all consecutive heterozygous FH patients above age 18 years, who were treated by a specialized team in the outpatient clinic of a university hospital in The Netherlands between 2008 and 2009. In addition to clinical data, patients completed a questionnaire concerning medication adherence.

Results: We analyzed 321 patients (169 women) with a statin prescription whose mean age was 46 ± 14 years (± S.D.), and 13 % of the patients had CHD. The untreated mean total cholesterol was 10 ± 2.3 mmol/l. On average, patients were ten years on cholesterol-lowering therapy (range 1-29 years). Adherence was reported by 89 % of the patients (> 90 % adherence). Non-adherence was associated with younger age (OR = 10.64, 95 % CI 2.86-39.68), high total cholesterol level during prescription (OR = 4.29, 95 % CI 1.86-9.89) and a relatively low untreated total cholesterol level (OR = 3.94 95 % CI 1.39-11.14). A prediction model based on these three determinants had a c-index of 0.78 and a calibration with P = 0.88.

Conclusion: Based on three independent determinants, a prediction model is developed to identify non-adherent FH patients. This model needs to be tested in future prospective research. It might be a first step in improving statin adherence in this extremely high risk group.

Citing Articles

A Systematic Review Uncovering Modifiable Influences on Statin Adherence.

Rosenberg J, Lampridou S, Moores A, Garfield S, Wingfield D, Judah G Patient Prefer Adherence. 2025; 19():29-48.

PMID: 39780938 PMC: 11708203. DOI: 10.2147/PPA.S502645.


Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis.

Iatan I, Akioyamen L, Ruel I, Guerin A, Hales L, Coutinho T Eur Heart J. 2024; 45(35):3231-3250.

PMID: 38976372 PMC: 11400737. DOI: 10.1093/eurheartj/ehae417.


Sex Differences in Familial Hypercholesterolemia.

Klevmoen M, Mulder J, Roeters van Lennep J, Holven K Curr Atheroscler Rep. 2023; 25(11):861-868.

PMID: 37815650 PMC: 10618303. DOI: 10.1007/s11883-023-01155-6.


Screening and treatment of familial hypercholesterolemia in a French sample of ambulatory care patients: A retrospective longitudinal cohort study.

Ferrieres J, Banks V, Pillas D, Giorgianni F, Gantzer L, Lekens B PLoS One. 2021; 16(8):e0255345.

PMID: 34339471 PMC: 8328334. DOI: 10.1371/journal.pone.0255345.


The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia.

Pang J, Chan D, Watts G Curr Atheroscler Rep. 2020; 22(11):64.

PMID: 32870376 PMC: 7459268. DOI: 10.1007/s11883-020-00884-2.


References
1.
de Geest S, Sabate E . Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003; 2(4):323. DOI: 10.1016/S1474-5151(03)00091-4. View

2.
Jansen A, van Aalst-Cohen E, Tanck M, Trip M, Lansberg P, Liem A . The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004; 256(6):482-90. DOI: 10.1111/j.1365-2796.2004.01405.x. View

3.
Marks R, Allegrante J, Lorig K . A review and synthesis of research evidence for self-efficacy-enhancing interventions for reducing chronic disability: implications for health education practice (part II). Health Promot Pract. 2005; 6(2):148-56. DOI: 10.1177/1524839904266792. View

4.
Rubak S, Sandbaek A, Lauritzen T, Christensen B . Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005; 55(513):305-12. PMC: 1463134. View

5.
Frisinghelli A, Mafrici A . Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review. Clin Drug Investig. 2007; 27(9):591-604. DOI: 10.2165/00044011-200727090-00001. View